Olfactory Neuroblastoma: Clinical Features and Treatment Outcome.
- Author:
Sung Kyun HWANG
1
;
Weon Jin SEONG
;
Yoon Kyung JEON
;
Je G CHI
;
Chull Hee LEE
;
Hee Won JUNG
Author Information
1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. hwnjung@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Olfactory neuroblastoma;
UCLA staging system;
Radiation therapy;
Metastasis;
Chemotherapy;
Recurrence
- MeSH:
Drug Therapy;
Epistaxis;
Esthesioneuroblastoma, Olfactory*;
Female;
Follow-Up Studies;
Headache;
Humans;
Male;
Medical Records;
Nasal Obstruction;
Neoplasm Metastasis;
Recurrence;
Retrospective Studies;
Survival Rate;
Treatment Outcome*
- From:Journal of Korean Neurosurgical Society
2003;33(5):446-453
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The authors analyzed clinical features, long-term treatment outcome, and prognostic factors of the olfactory neuroblastoma. METHODS: Twenty-one cases of olfactory neuroblastomas, treated from 1979 to 2000, were retrospectively reviewed with medical records and radiological findings. Mean follow-up periods are 28.7 months(range 4-178). Extent of tumor was classified by UCLA staging system. Statistical analysis for survival was done using Kaplan Meier method and log-lank test. RESULTS: Mean age was 27 years(13-62), and most common group are second decades(8/21, 38%). Male to female ratio was 13: 8. Common symptoms are nasal obstruction, epistaxis, exopthalmos and headache. There were three cases of T1, five T2, six T3, and seven T4 according to UCLA staging system. The 5-year survival rate was 21.3% and average time was 28.9 months in surgical resection group(n=14) as primary modality have higher survival rate than radiation and chemotherapy group(n=7)[2-year survival rate: 39.2% vs 14.3%, 5-year survival rate: 19.6% vs 14.3%(p=0.0274)]. Early stage(T1, T2) groups showed better survival rate than advanced(T3, T4) groups(38.1% vs 9.1% p=0.0336). The local and regional recurrences were observed in 6(27%) and 2(9%) cases. Mean recurrence free time was 7.8 months(range 1-25). CONCLUSION: Early detection and extent of resection are the important prognostic factors. Regular follow up is mandatary for the detection of recurrence or metastasis.
